Adebrelimab and dalpiciclib with chemotherapy before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of two experimental drugs (adebrelimab and dalpiciclib) with standard chemotherapy given before surgery for head and neck cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer is locally advanced but still removable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of head and neck cancer (called squamous cell carcinoma) that is locally advanced but can be surgically removed.
- You have not had any previous treatment (like chemotherapy or radiation) for this cancer.
- You are in good enough health to be fairly active (able to do light housework or office work).
- You have adequate kidney, liver, and blood function, as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a new combination of two investigational drugs (adebrelimab and dalpiciclib) given before surgery for locally advanced head and neck cancer that is not linked to HPV. The goal is to see if these drugs can shrink the tumor and possibly improve outcomes.
This trial tests whether adding a PD-L1 antibody (Adabelimab) to standard chemotherapy before surgery can help treat advanced head and neck squamous cell carcinoma. It is for people who have not had treatment for this cancer before and are well enough to undergo the therapy.
This trial tests a new combination of two drugs (dalpiciclib and cetuximab) versus cetuximab alone for people with head and neck cancer that is HPV-negative, has not responded to prior immunotherapy, and is not curable with surgery. The goal is to see if the combination works better.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.